Protalix BioTherapeutics
| Company type | Public |
|---|---|
| AMEX: PLX TASE: PLX | |
| Industry | Biotechnology |
| Founded | 1993 |
| Founder | Yoseph Shaaltiel |
| Headquarters | , |
Key people | Shlomo Yanai (Interim Chairman) Moshe Manor (CEO) |
| Products | Elelyso |
| Revenue | $11.51 million (2013) |
| Total assets | $113.33 million (2013) |
Number of employees | 266 (2013) |
| Website | protalix |
| Footnotes / references | |
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.